首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
【24h】

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

机译:一线诱导化疗后表现良好状态仍未进展的IIIb / IV期非小细胞肺癌(NSCLC)患者维持治疗的贝叶斯网络荟萃比较:按表现状态,EGFR突变,组织学和对既往反应的结果感应

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Recent trials have suggested that maintenance treatments improve outcomes for patients not progressing after first-line therapy for advanced non-small-cell lung cancer (NSCLC). However, physicians have little guidance on selecting which patients benefit the most and what drug or regimen is optimal. Here, we report a systematic review and network meta-analysis of maintenance treatments in subgroups determined by performance status (PS), epidermal growth factor receptor (EGFR) mutation, histology and response to induction.
机译:背景:最新试验表明,对于晚期非小细胞肺癌(NSCLC)的一线治疗,维持治疗可以改善未进展的患者的预后。但是,医生在选择哪些患者受益最大以及哪种药物或治疗方案最佳方面没有指导。在这里,我们报告了由表现状态(PS),表皮生长因子受体(EGFR)突变,组织学和对诱导的反应所决定的亚组中维持治疗的系统评价和网络荟萃分析。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号